RxDoctor Payments Data

Kurt Kinney, MD

Cardiovascular Disease · Tacoma, WANPI 1922015296

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $4,310 of the $6,645 with a category attached, or 64.9%. 11 manufacturers reported payments, led by Abbott at 54.5% of the total. Reporting peaked in 2023 at $2,433 and has fallen 87.5% since, to $305 in 2025.

$6,645in general payments, 2019–2025

Across 71 payments — averaging $93.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$4K
  • Edwards Lifesciences$2K
  • Abiomed$195
  • Novartis$80
  • Opsens Inc.$65
  • Cardiva Medical, Inc.$53
  • plus $144 from 5 others
$9,620in research payments, 2019–2025

Across 11 payments — averaging $874.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • W. L. Gore & Associates, Inc.$10K

What the payments were for

  • Travel & lodging$4,31065%
  • Food & beverage$2,31735%
  • Entertainment$180%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,645 in reported general payments places this provider in the 85th percentile of 370 cardiovascular disease providers in Washington.

See all cardiovascular disease providers in Washington

Medicare billing

Part B allowed, 2024
$311,906
Medicare patients
964
Services billed
2,332

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban293$389,603
XareltoRivaroxaban225$216,210
Ambrisentan12$34,200
EntrestoSacubitril/Valsartan29$31,525
FarxigaDapagliflozin Propanediol14$14,242
JardianceEmpagliflozin16$11,042
Metoprolol Succinate662$8,975
Isosorbide Dinitrate45$8,063
Atorvastatin Calcium493$4,431
Ranolazine ErRanolazine40$4,272
Isosorbide Mononitrate ErIsosorbide Mononitrate329$4,019
Midodrine Hcl26$3,597
ClopidogrelClopidogrel Bisulfate291$3,106
Potassium Chloride127$3,048
Furosemide297$2,279

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$49$216,210225 claims
NovartisEntresto$80$31,52529 claims
AstraZenecaFarxiga$26$14,24214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 370 cardiovascular disease providers in Washington.

Other cardiovascular disease in Tacoma

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →